Beiersdorf's $2.52 EPS Hides a Real-World Split: Derma Works, NIVEA Still Needs Help

Beiersdorf's 2025 numbers still look stable, but portfolio visibility is the real test

On paper, Beiersdorf still looks manageable. Full-year 2025 delivered EPS of EUR 4.25, and management is still targeting an 11.8% EBIT margin ex-special factors for 2026. That is why the story matters now: the market can absorb a soft number, but it is less forgiving when visibility on demand deteriorates.

In 2025, Beiersdorf still posted 2.4% organic sales growth in a slowed skincare market. Even then, the split inside the portfolio was hard to miss: NIVEA underperformed (0.9% organic growth) while Derma kept expanding at a double-digit rate.

By the first half of 2026, that divide mattered more. Group sales declined by 3.5% organically and Consumer sales decreased organically by 4.0%, with continued pressure on NIVEA. Management still sees margin discipline and a path back to growth in 2027, but investors increasingly need proof that the weak spot is turning, not just a promise that it will.

Derma is passing the demand test; NIVEA still needs a real recovery

A clearer way to assess Beiersdorf now is to judge the portfolio by brand, not just by the group headline.

Eucerin and Aquaphor are still showing durable demand

Derma remains the strongest part of the portfolio. It posted record EUR 1.5 billion in net sales and broad-based double-digit growth across Europe, North America, and emerging markets. That looks less like a temporary boom and more like repeat-purchase demand backed by product differentiation.

Beiersdorf also said Derma's performance was driven by innovation and expansion into white spaces. Taken together, the evidence points to a franchise that is still gaining traction rather than simply harvesting existing demand.

La Prairie has improved, but it is still early to call it a full turnaround

La Prairie is the middle case. Management said it returned to net sales growth in Q2 as temporary retail disruptions faded, and a new entry line is scheduled for September. That is encouraging, but the luxury brand is still uneven enough that one quarter of improvement is not the same as a fully validated recovery.

NIVEA remains the main execution risk

NIVEA is still the brand where the demand test is not passing. NIVEA net sales dynamics remain challenged, even as management says its rebalancing strategy is showing some initial positive effects on market share and volume. To keep the 2026 outlook credible, Beiersdorf now needs that turnaround plan to translate into better consumer demand, not just better messaging.

What has to happen for the stock story to improve

What matters now is not another EPS debate. It is whether Beiersdorf can show that the strong parts of the portfolio are durable, the weak part is actually improving, and shareholder returns are supporting the story rather than masking weakness.

The company still entered 2026 from a strong base with a 14.0% EBIT margin in 2025. For 2026, the published hurdle is an 11.8% EBIT margin excl. special factors. If management holds that line while demand improves, confidence can build. If not, investors may simply be asked to wait longer for proof that the turnaround is working.